AngioDynamics, Inc. (NASDAQ:ANGO) – Equities researchers at KeyCorp boosted their Q3 2018 earnings per share estimates for AngioDynamics in a research note issued on Thursday. KeyCorp analyst M. Mishan now forecasts that the medical instruments supplier will post earnings of $0.20 per share for the quarter, up from their prior forecast of $0.18. KeyCorp currently has a “Hold” rating on the stock. KeyCorp also issued estimates for AngioDynamics’ Q4 2018 earnings at $0.26 EPS, FY2018 earnings at $0.75 EPS and FY2019 earnings at $0.91 EPS.

Several other analysts have also weighed in on the company. BidaskClub lowered AngioDynamics from a “hold” rating to a “sell” rating in a report on Saturday. Craig Hallum lowered AngioDynamics from a “buy” rating to a “hold” rating in a report on Friday. TheStreet lowered AngioDynamics from a “b-” rating to a “c” rating in a report on Tuesday, January 2nd. Canaccord Genuity restated a “hold” rating and issued a $17.00 price objective on shares of AngioDynamics in a report on Sunday, October 8th. Finally, Zacks Investment Research upgraded AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a report on Tuesday, October 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $18.60.

Shares of AngioDynamics (NASDAQ ANGO) opened at $16.11 on Monday. The company has a quick ratio of 1.65, a current ratio of 2.56 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $591.97, a price-to-earnings ratio of -76.71, a PEG ratio of 1.57 and a beta of 1.04. AngioDynamics has a twelve month low of $14.80 and a twelve month high of $18.85.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Thursday, January 4th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.16. AngioDynamics had a positive return on equity of 4.63% and a negative net margin of 2.27%. The company had revenue of $86.70 million during the quarter, compared to analyst estimates of $88.15 million. During the same quarter in the previous year, the firm posted $0.19 EPS. The firm’s quarterly revenue was down 2.6% on a year-over-year basis.

Several institutional investors have recently made changes to their positions in the company. Stevens Capital Management LP lifted its holdings in shares of AngioDynamics by 0.8% in the second quarter. Stevens Capital Management LP now owns 24,488 shares of the medical instruments supplier’s stock valued at $397,000 after buying an additional 188 shares during the period. Acrospire Investment Management LLC raised its position in shares of AngioDynamics by 3.7% during the second quarter. Acrospire Investment Management LLC now owns 8,915 shares of the medical instruments supplier’s stock worth $145,000 after purchasing an additional 317 shares during the period. Comerica Bank raised its position in shares of AngioDynamics by 2.5% during the second quarter. Comerica Bank now owns 36,068 shares of the medical instruments supplier’s stock worth $606,000 after purchasing an additional 893 shares during the period. Arizona State Retirement System raised its position in shares of AngioDynamics by 7.2% during the second quarter. Arizona State Retirement System now owns 17,796 shares of the medical instruments supplier’s stock worth $288,000 after purchasing an additional 1,200 shares during the period. Finally, Public Employees Retirement System of Ohio raised its position in shares of AngioDynamics by 7.8% during the second quarter. Public Employees Retirement System of Ohio now owns 28,259 shares of the medical instruments supplier’s stock worth $458,000 after purchasing an additional 2,050 shares during the period. Institutional investors and hedge funds own 95.23% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/q3-2018-eps-estimates-for-angiodynamics-inc-ango-increased-by-analyst/1798430.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with Analyst Ratings Network's FREE daily email newsletter.